{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:33:49Z","timestamp":1790836429944,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Assessment of the cumulative incidence of SARS-CoV-2 infections is critical for monitoring the course and extent of the COVID-19 epidemic. Here, we report estimated seroprevalence in the French population and the proportion of infected individuals who developed neutralising antibodies at three points throughout the first epidemic wave. Testing 11,000 residual specimens for anti-SARS-CoV-2 IgG and neutralising antibodies, we find nationwide seroprevalence of 0.41% (95% CI: 0.05\u20130.88) mid-March, 4.14% (95% CI: 3.31\u20134.99) mid-April and 4.93% (95% CI: 4.02\u20135.89) mid-May 2020. Approximately 70% of seropositive individuals have detectable neutralising antibodies. Infection fatality rate is 0.84% (95% CI: 0.70\u20131.03) and increases exponentially with age. These results confirm that the nationwide lockdown substantially curbed transmission and that the vast majority of the French population remained susceptible to SARS-CoV-2 in May 2020. Our study shows the progression of the first epidemic wave and provides a framework to inform the ongoing public health response as viral transmission continues globally.<\/jats:p>","DOI":"10.1038\/s41467-021-23233-6","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T06:02:50Z","timestamp":1621576970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1303-8281","authenticated-orcid":false,"given":"St\u00e9phane","family":"Le Vu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9441-4172","authenticated-orcid":false,"given":"Gabrielle","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Anna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4193-9159","authenticated-orcid":false,"given":"Jean-Baptiste","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Bernard-Stoecklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Goyard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1103-6805","authenticated-orcid":false,"given":"Caroline","family":"Demeret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Helynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Escriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Gransagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Petres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgile","family":"Monnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2821-4759","authenticated-orcid":false,"given":"Louise","family":"Perrin de Facci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Ungeheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"L\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonnick","family":"Guillois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Filleul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Charneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"L\u00e9vy-Bruhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-4456","authenticated-orcid":false,"given":"Sylvie","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3011-9267","authenticated-orcid":false,"given":"Harold","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"23233_CR1","doi-asserted-by":"crossref","unstructured":"Bernard Stoecklin, S. et al. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro. Surveill. 25, 200009 (2020).","DOI":"10.2807\/1560-7917.ES.2020.25.6.2000094"},{"key":"23233_CR2","doi-asserted-by":"publisher","unstructured":"Carrat, F. et al. Seroprevalence of SARS-CoV-2 among adults in three regions of France following the lockdown and associated risk factors: a multicohort study. medRxiv https:\/\/doi.org\/10.1101\/2020.09.16.20195693 (2020).","DOI":"10.1101\/2020.09.16.20195693"},{"key":"23233_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.15585\/mmwr.mm6923e4","volume":"69","author":"DC Payne","year":"2020","unstructured":"Payne, D. C. et al. SARS-CoV-2 infections and serologic responses from a sample of U.S. Navy Service Members\u2014USS Theodore Roosevelt, April 2020. Morb. Mortal. Wkly Rep. 69, 714\u2013721 (2020).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"23233_CR4","doi-asserted-by":"publisher","unstructured":"Poll\u00e1n, M. et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet https:\/\/doi.org\/10.1016\/s0140-6736(20)31483-5 (2020).","DOI":"10.1016\/s0140-6736(20)31483-5"},{"key":"23233_CR5","doi-asserted-by":"publisher","unstructured":"Ward, H. et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. medRxiv https:\/\/doi.org\/10.1101\/2020.08.12.20173690 (2020).","DOI":"10.1101\/2020.08.12.20173690"},{"key":"23233_CR6","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1056\/NEJMp2002125","volume":"382","author":"M Lipsitch","year":"2020","unstructured":"Lipsitch, M., Swerdlow, D. L. & Finelli, L. Defining the epidemiology of Covid-19\u2014studies needed. N. Engl. J. Med. 382, 1194\u20131196 (2020).","journal-title":"N. Engl. J. Med."},{"key":"23233_CR7","doi-asserted-by":"publisher","unstructured":"Aziz, N. A. et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies: results from a population-based study in Bonn, Germany. medRxiv https:\/\/doi.org\/10.1101\/2020.08.24.20181206 (2020).","DOI":"10.1101\/2020.08.24.20181206"},{"key":"23233_CR8","doi-asserted-by":"publisher","unstructured":"Roederer, T. et al. High seroprevalence of SARS-CoV-2 antibodies among people living in precarious situations in Ile de France. medRxiv https:\/\/doi.org\/10.1101\/2020.10.07.20207795 (2020).","DOI":"10.1101\/2020.10.07.20207795"},{"key":"23233_CR9","doi-asserted-by":"publisher","unstructured":"Skowronski, D. M. et al. Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020. medRxiv https:\/\/doi.org\/10.1101\/2020.07.13.20153148 (2020).","DOI":"10.1101\/2020.07.13.20153148"},{"key":"23233_CR10","doi-asserted-by":"publisher","unstructured":"Thompson, C. et al. Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors\u2014a pilot study of the value of serology to determine population exposure. medRxiv https:\/\/doi.org\/10.1101\/2020.04.13.20060467 (2020).","DOI":"10.1101\/2020.04.13.20060467"},{"key":"23233_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18450-4","volume":"11","author":"AT Huang","year":"2020","unstructured":"Huang, A. T. et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. Nat. Commun. 11, 4704 (2020).","journal-title":"Nat. Commun."},{"key":"23233_CR12","doi-asserted-by":"publisher","unstructured":"Herzog, S. et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples. medRxiv https:\/\/doi.org\/10.1101\/2020.06.08.20125179 (2020).","DOI":"10.1101\/2020.06.08.20125179"},{"key":"23233_CR13","doi-asserted-by":"publisher","unstructured":"Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet https:\/\/doi.org\/10.1016\/S0140-6736(20)31304-0 (2020).","DOI":"10.1016\/S0140-6736(20)31304-0"},{"key":"23233_CR14","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1126\/science.abc3517","volume":"369","author":"H Salje","year":"2020","unstructured":"Salje, H. et al. Estimating the burden of SARS-CoV-2 in France. Science 369, 208\u2013211 (2020).","journal-title":"Science"},{"key":"23233_CR15","doi-asserted-by":"crossref","unstructured":"O\u2019Driscoll, M. et al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 1\u20139 (2020).","DOI":"10.1038\/s41586-020-2918-0"},{"key":"23233_CR16","doi-asserted-by":"publisher","unstructured":"Ioannidis, J. The infection fatality rate of COVID-19 inferred from seroprevalence data. medRxiv https:\/\/doi.org\/10.1101\/2020.05.13.20101253 (2020).","DOI":"10.1101\/2020.05.13.20101253"},{"key":"23233_CR17","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.3390\/jcm9103148","volume":"9","author":"P-Y Bo\u00eblle","year":"2020","unstructured":"Bo\u00eblle, P.-Y. et al. Trajectories of Hospitalization in COVID-19 patients: an observational study in France. J. Clin. Med. 9, 3148 (2020).","journal-title":"J. Clin. Med."},{"key":"23233_CR18","doi-asserted-by":"publisher","unstructured":"Fontanet, A. et al. SARS-CoV-2 infection in primary schools in northern France: a retrospective cohort study in an area of high transmission. medRxiv https:\/\/doi.org\/10.1101\/2020.06.25.20140178 (2020).","DOI":"10.1101\/2020.06.25.20140178"},{"key":"23233_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-020-00677-5","volume":"10","author":"K Kuteifan","year":"2020","unstructured":"Kuteifan, K., Pasquier, P., Meyer, C., Escarment, J. & Theissen, O. The outbreak of COVID-19 in Mulhouse: hospital crisis management and deployment of military hospital during the outbreak of COVID-19 in Mulhouse, France. Ann. Intensive Care 10, 59 (2020).","journal-title":"Ann. Intensive Care"},{"key":"23233_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/eji.202049058","volume":"51","author":"F Anna","year":"2021","unstructured":"Anna, F. et al. High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris. Eur. J. Immunol. 51, 180\u2013190 (2021).","journal-title":"Eur. J. Immunol."},{"key":"23233_CR21","doi-asserted-by":"publisher","unstructured":"Fafi-Kremer, S. et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. medRxiv https:\/\/doi.org\/10.1101\/2020.05.19.20101832 (2020).","DOI":"10.1101\/2020.05.19.20101832"},{"key":"23233_CR22","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"23233_CR23","doi-asserted-by":"publisher","unstructured":"Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-020-0897-1 (2020).","DOI":"10.1038\/s41591-020-0897-1"},{"key":"23233_CR24","doi-asserted-by":"publisher","unstructured":"Bolotin, S. et al. SARS-CoV-2 seroprevalence survey estimates are affected by anti-nucleocapsid antibody decline. medRxiv https:\/\/doi.org\/10.1101\/2020.09.28.20200915 (2020).","DOI":"10.1101\/2020.09.28.20200915"},{"key":"23233_CR25","doi-asserted-by":"publisher","unstructured":"Emmenegger, M. et al. Early peak and rapid decline of SARS-CoV-2 seroprevalence in a Swiss metropolitan region. medRxiv https:\/\/doi.org\/10.1101\/2020.05.31.20118554 (2020).","DOI":"10.1101\/2020.05.31.20118554"},{"key":"23233_CR26","doi-asserted-by":"publisher","unstructured":"Flamand, C. et al. Seroprevalence of anti-SARS-CoV-2 IgG at the epidemic peak in French Guiana. medRxiv https:\/\/doi.org\/10.1101\/2020.09.27.20202465 (2020).","DOI":"10.1101\/2020.09.27.20202465"},{"key":"23233_CR27","unstructured":"Autorit\u00e9 de la concurrence. D\u00e9cision no. 20-DCC-90 du 17 juillet 2020 relative \u00e0 la prise de contr\u00f4le exclusif du groupe Laborizon par le groupe Biogroup. https:\/\/www.autoritedelaconcurrence.fr\/sites\/default\/files\/integral_texts\/2020-08\/20-033_version_publique.pdf (2020)."},{"key":"23233_CR28","doi-asserted-by":"publisher","unstructured":"Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature https:\/\/doi.org\/10.1038\/s41586-020-2405-7 (2020).","DOI":"10.1038\/s41586-020-2405-7"},{"key":"23233_CR29","doi-asserted-by":"crossref","unstructured":"Grzelak, L. et al. A comparison of four serological assays for detecting anti\u2013SARS-CoV-2 antibodies in human serum samples from different populations. Sci. Transl. Med. 12, eabc3103 (2020).","DOI":"10.1126\/scitranslmed.abc3103"},{"key":"23233_CR30","doi-asserted-by":"publisher","unstructured":"Goyard, S. et al. A highly sensitive bioluminescent method for measuring allergen-specific IgE in microliter samples. Allergy https:\/\/doi.org\/10.1111\/all.14365 (2020) .","DOI":"10.1111\/all.14365"},{"key":"23233_CR31","doi-asserted-by":"crossref","unstructured":"Gelman, A. & Carpenter, B. Bayesian analysis of tests with unknown specificity and sensitivity. http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.05.22.20108944 (2020).","DOI":"10.1101\/2020.05.22.20108944"},{"key":"23233_CR32","unstructured":"Insee. Estimation de la population au 1er janvier 2020. https:\/\/www.insee.fr\/fr\/statistiques\/1893198 (2020)."},{"key":"23233_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/oxfordjournals.aje.a112510","volume":"107","author":"WJ Rogan","year":"1978","unstructured":"Rogan, W. J. & Gladen, B. Estimating prevalence from the results of a screening test. Am. J. Epidemiol. 107, 71\u201376 (1978).","journal-title":"Am. J. Epidemiol."},{"key":"23233_CR34","unstructured":"Stan Development Team. RStan: the R interface to Stan. http:\/\/mc-stan.org\/ (2020)."},{"key":"23233_CR35","unstructured":"R Core Team. R: a language and environment for statistical computing. https:\/\/www.R-project.org\/ (2019)."},{"key":"23233_CR36","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/M20-0504","volume":"172","author":"SA Lauer","year":"2020","unstructured":"Lauer, S. A. et al. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann. Intern. Med. 172, 577\u2013582 (2020).","journal-title":"Ann. Intern. Med."},{"key":"23233_CR37","unstructured":"Sant\u00e9 publique France. COVID-19: Point \u00e9pid\u00e9miologique hebdomadaire du 24 septembre 2020. https:\/\/www.santepubliquefrance.fr\/content\/download\/283689\/2742445 (2020)."},{"key":"23233_CR38","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S1473-3099(20)30584-3","volume":"21","author":"J Perez-Saez","year":"2021","unstructured":"Perez-Saez, J. et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect. Dis. 21, e69\u2013e70 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"23233_CR39","unstructured":"Etalab. Suivi de l\u2019\u00e9pid\u00e9mie en france. https:\/\/dashboard.covid19.data.gouv.fr\/ (2020)."},{"key":"23233_CR40","unstructured":"Etalab. Open platform for French public data. https:\/\/www.data.gouv.fr\/fr\/datasets\/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19\/ (2020)."},{"key":"23233_CR41","doi-asserted-by":"publisher","unstructured":"Le Vu, S. serpico2. (Zenodo, 2021). https:\/\/doi.org\/10.5281\/zenodo.4586147.","DOI":"10.5281\/zenodo.4586147"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23233-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T07:40:48Z","timestamp":1669966848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-23233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["23233"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-23233-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.10.20.20213116","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.G. and T.R. declare patents for the proluciferins (hikarazines) synthesis and uses (\u201cImidazopyrazine derivatives, process for preparation thereof and their uses as luciferins\u201d, EP 3395803\/WO 2018197727, 2018), and have applied for a patent that includes claims describing the LuLISA (EP20315224.4) used in this study. F.A. and P.C. have applied for a patent claiming the PNT (\u201cHigh throughput methods and products for SARS-CoV-2 sero-neutralization assay\u201d US 63\/107,896). N.E., M.G., C.D. and S.v.d.W. declare patents pending for the SARS-associated coronavirus diagnostics (\u201cSevere acute respiratory syndrome (SARS)-associated coronavirus diagnostics\u201d, US 10,948,490 B1) related to this study. S.v.d.W. and N.E. declare patents issued (\u201cUse of proteins and peptides coded by the genome of a novel strain of SARS-associated coronavirus\u201d EP 1697507; and \u201cNovel strain of SARS-associated coronavirus and applications thereof\u201d EP1694829) not directly related to this study. S.v.d.W. is a board member (non-financial support) for the International Society for Influenza and other Respiratory Virus Diseases and has a patent application filed (\u201cMethods and reagents for the specific and sensitive detection of SARS-CoV-2\u201d, PCT\/EP2020055939 and US16\/809,717), not directly related to this study. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3025"}}